Table 2.

SCr-AKI diagnostic characteristics of AKI biomarkers at early and late cisplatin visits

Time Point	Area Under Receiver Operating Characteristic Curve (95% Confidence Interval)	Optimal Biomarker Concentration Cutoffa	Sensitivity (%)	Specificity (%)	Biomarker Concentration for ≥85% Sensitivitya	Specificity Associated with ≥85% Sensitivity (%)	Biomarker Concentration for ≥85% Specificitya	Sensitivity Associated with ≥85% Specificity (%)
Urine NGAL for SCr-AKI at early visit
Pre-infusion (n=150)	0.56 (0.46 to 0.67)	36.7	39	83	3.1	12	53.2	26
Pos-tinfusion (n=148)	0.60 (0.49 to 0.70)	8.7	74	47	4.5	19	54.8	28
Discharge (n=146)	0.65 (0.54 to 0.75)	15.5	71	57	5.7	25	59.9	37
Urine KIM-1 for SCr-AKI at early visit
Pre-infusion (n=150)	0.48 (0.36 to 0.59)	3269	15	100	119	12	1246	24
Post-infusion (n=148)	0.56 (0.45 to 0.67)	573	42	78	91	10	959	28
Discharge (n=146)	0.61 (0.51 to 0.71)	1649	63	58	458	32	5165	22
Urine NGAL for SCr-AKI at late visit
Pre-infusion (n=120)	0.64 (0.50 to 0.79)	31.4	65	77	5.3	25	60.3	35
Post-infusion (n=123)	0.69 (0.56 to 0.82)	23.1	62	74	7.5	38	63.1	33
Discharge (n=116)	0.71 (0.57 to 0.86)	44.2	55	89	6.1	33	41.4	55
Urine KIM-1 for SCr-AKI at late visit
Pre-infusion (n=120)	0.54 (0.38 to 0.70)	4776	20	99	134	11	1474	30
Post-infusion (n=123)	0.64 (0.52 to 0.77)	253	81	46	193	36	1549	33
Discharge (n=116)	0.75 (0.63 to 0.86)	2030	80	65	1648	60	5360	45

SCr-AKI, serum creatinine–defined AKI; NGAL, neutrophil gelatinase-associated lipocalin; discharge, hospital discharge; KIM-1, kidney injury molecule-1.

^aOptimal biomarker concentration cutoff: maximum combined sensitivity and specificity. Units for urine NGAL, ng/mg creatinine. Units for urine KIM-1, pg/mg creatinine.